Rhodococcus Equi Infection: What the Research Says
Evidence from 27 peer-reviewed studies
What Professionals Should Know
- •Doxycycline can replace rifampin as a combination partner with azithromycin for treating bronchopneumonia in foals, providing a viable alternative if rifampin becomes unavailable or restricted
- •Both combination treatments showed excellent efficacy (98-100%) compared to no treatment (73%), supporting prompt antimicrobial intervention for foals with pulmonary lesions
- •Individual farm conditions and R. equi prevalence may affect outcomes, so monitor treatment response and adjust protocols based on local epidemiology
- •Uveitis and joint swelling in foals with R. equi pneumonia indicate septic infection requiring aggressive systemic antimicrobial therapy; these are not simply secondary immune reactions
- •Disease severity in the lungs directly predicts risk of systemic dissemination to joints and eyes, so early detection and treatment of respiratory signs is critical to prevent complications
- •Foals presenting with concurrent polysynovitis and uveitis should be assumed to have active septic infection in these tissues until proven otherwise, guiding diagnostic and therapeutic decisions
- •Expect anhidrosis (impaired sweating) in foals treated with any macrolide antibiotic (erythromycin, azithromycin, clarithromycin) for Rhodococcus equi pneumonia; monitor closely during exercise and hot weather to prevent heat stress
- •Azithromycin and clarithromycin are safer alternatives to erythromycin if sweating capacity is a concern, though both still cause some sweat suppression
- •Adding rifampicin to erythromycin does not significantly protect against anhidrosis and should not be relied upon to mitigate this side effect
- •Do not automatically treat foals with small subclinical pulmonary lesions (5-10 cm) identified on ultrasound—most will self-resolve without medication
- •Reserve antimicrobial therapy for foals showing clinical signs of disease progression; empiric mass treatment on endemic farms is unnecessary and exposes healthy foals to unnecessary medication
- •If treatment is deemed necessary, azithromycin-rifampin may shorten treatment duration, but does not accelerate lesion resolution compared to watchful waiting
- •REHIP transfusion temporarily elevates cortisol in foals; monitor for stress responses, with higher elevations at 2 L doses
- •The inverse relationship between cortisol and immunoglobulin activity suggests a potential stress-immune trade-off, but this does not impair protection against rhodococcal pneumonia in clinical practice
- •Cortisol elevation alone should not be used as a predictor of rhodococcal pneumonia risk in transfused foals
- •Metabolomic biomarkers could help identify which foals with subclinical R. equi lesions actually need antibiotic treatment, reducing unnecessary antimicrobial use on endemic farms
- •This approach may prevent unnecessary treatment of the ~80% of foals with ultrasonographic lesions that would not progress to clinical disease
- •Implementing metabolomic screening could improve selective medication strategies while maintaining animal welfare on R. equi-endemic operations
- •Conformational manifestations of DOD represent a significant perinatal mortality risk; farriers and vets should anticipate potential congenital limb alignment issues in young Thoroughbreds presenting with clinical signs
- •Rhodococcus equi pneumonia is the primary infectious cause of death in pre-weaning foals; early recognition of respiratory signs and environmental management (dust, aerosol control) are critical during the 1-4 month window
- •Mortality patterns shift dramatically with age, suggesting different preventive strategies are needed for neonates versus weaners—perinatal defects require management at birth, while infectious disease prevention focuses on the pre-weaning period
- •When interpreting nasal culture results, understand that Staphylococcus spp., Bacillus spp., and Gram-negative bacilli are normal commensals in healthy horses and their presence alone does not confirm infection
- •Be aware that pathogenic organisms like S. equi equi and R. equi can be present in clinically healthy horses; clinical signs and culture context must guide treatment decisions to avoid unnecessary antimicrobial use
- •Use this baseline data on normal URT microbiota profiles to improve diagnostic accuracy and develop targeted antimicrobial therapy protocols for horses with respiratory disease
- •Lipidomic profiling may enable identification of foals truly at risk for clinical R. equi pneumonia, potentially reducing unnecessary antimicrobial use in cases with self-limiting infections
- •Longitudinal lipid biomarkers could help clinicians make more informed treatment decisions for foals with ultrasonographic lung lesions
- •This approach may contribute to antimicrobial stewardship in equine practice by distinguishing which infected foals genuinely require therapy
- •When treating foals with severe Rhodococcus equi lung abscesses, consider gamithromycin with rifampicin as an alternative to clarithromycin-rifampicin combinations to avoid problematic drug interactions
- •Gamithromycin's poor metabolism profile makes it a more compatible partner drug with enzyme-inducing agents like rifampicin compared to other macrolides
- •Monitor foals receiving combined rifampicin therapy carefully, as enzyme induction can significantly alter macrolide antibiotic pharmacokinetics and treatment efficacy
- •Do not rely on air sampling from young foal breathing zones as a predictor of which foals will develop rhodococcal pneumonia—ultrasonographic screening remains the preferred early detection method
- •Air sampling may still have value as a herd-level epidemiological tool for older foals, but should not guide individual foal diagnosis or treatment decisions in neonates
- •Continue using routine ultrasonographic screening at 1-2 months of age as the standard for early detection of subclinical rhodococcal pneumonia in breeding operations
- •This R. equi strain shows significant virulence potential and multiple drug resistance genes—antimicrobial susceptibility testing should guide treatment selection in affected foals
- •The documented pathogenic mechanisms involving immune dysregulation highlight the need for supportive immunomodulatory care alongside antimicrobial therapy in R. equi cases
- •Genomic characterization of farm isolates can identify particularly virulent strains, informing biosecurity protocols on breeding farms
- •Recognize R. equi as an emerging pathogen in alpacas and other New World camelids; consider it in differential diagnosis for septicemia and aspiration pneumonia
- •R. equi isolates from this case showed broad antibiotic susceptibility, supporting therapeutic options if infection is suspected, though early diagnosis and treatment are critical given rapid septicemic progression
- •Apply One Health principles when managing R. equi cases in camelid herds due to documented zoonotic potential; implement appropriate biosecurity and occupational safety measures
- •Erythromycin-induced anhidrosis in foals involves specific genetic/molecular pathways affecting sweat gland function that may be reversible, warranting careful monitoring during treatment for Rhodococcus equi
- •Understanding the ion-channel and ubiquitin dysregulation mechanisms could help veterinarians develop targeted interventions or management strategies for foals experiencing macrolide-related anhidrosis
- •The molecular overlap between temporary (drug-induced) and heritable anhidrosis suggests potential therapeutic targets that warrant further investigation
- •R. equi can cause serious infections in immunocompromised humans; equine practitioners should recognize this as a zoonotic concern, particularly when handling foals with R. equi pneumonia
- •The presence of equine-type virulence plasmids in human isolates confirms horses as potential transmission sources—appropriate biosecurity and hygiene protocols are warranted in equine facilities
- •Virulence plasmids may not be essential for causing disease in severely immunosuppressed patients, complicating diagnosis and control strategies
- •Newborn foals have inherently reduced immune gene expression that may explain their higher susceptibility to R. equi; protective immune responses develop progressively over the first 8 weeks of life
- •Early-life infection risk appears highest in the first 1-2 weeks when MHC class II and other immune genes are not yet upregulated — timing aligns with clinical observations of neonatal R. equi disease
- •These molecular pathways could be targets for future preventative strategies (vaccines, immune-boosting therapies) in high-risk foals, though clinical translation remains to be developed
- •R. equi foal infections involve complex plasmid transfer between strains in the environment, meaning infection sources may be more dynamic than previously thought
- •Both virulent and avirulent R. equi are present in normal horse feces and pasture environments, so complete elimination from facilities is likely impossible
- •Knowing plasmid transfer occurs between strains may inform biosecurity and management strategies to reduce foal exposure to virulent isolates
- •Avirulent R equi can cause abortion in mares despite being considered non-pathogenic; clinicians should consider this organism in cases of unexplained fetal loss
- •Faecal shedding by mares represents a potential source of intrauterine infection; maintain hygiene and monitor mares with diarrhoea during pregnancy
- •Post-abortion serology and bacteriology of intrauterine fluids are valuable diagnostic tools when placental tissue is unavailable
- •Rhodococcus equi should be considered in the differential diagnosis for equine abortion, particularly in cases with pyogranulomatous lung lesions on necropsy
- •Environmental contamination with R. equi poses intrauterine infection risk to pregnant mares; biosecurity and farm management practices warrant attention on farms with abortion cases
- •Immunohistochemistry detection of VapA can assist in confirming R. equi diagnosis in aborted fetuses when bacteriology results are pending
- •R. equi is actively circulating in Kazakhstan with foals at significantly higher risk; practitioners in affected regions should maintain awareness of clinical signs and consider screening of foals on farms with known exposure
- •The clustering pattern in Almaty suggests management or environmental factors facilitate transmission on some farms—investigate biosecurity, housing density, and foal hygiene protocols on affected operations
- •Standardized serological screening protocols validated against reference standards could help identify high-risk farms and guide targeted preventive measures
- •Nebulization of platelet lysate appears technically feasible for delivery to equine lungs based on particle size characteristics, but clinical efficacy remains unproven
- •Results against R. equi are concerning—platelet lysate may not inhibit and could potentially support growth of this pneumonia pathogen in horses; do not use for suspected R. equi pneumonia until further research clarifies this finding
- •This is early-stage research; wait for in vivo studies before considering platelet lysate nebulization as a treatment option for equine respiratory disease in your practice
- •This qPCR test enables faster diagnosis of R. equi in foals compared to traditional culture methods, allowing earlier treatment decisions
- •The test simultaneously identifies macrolide resistance genes, helping practitioners select appropriate antibiotics and avoid ineffective treatments in MDR cases
- •Practitioners can obtain resistance profile results during the same diagnostic window as infection confirmation, improving treatment efficiency and potentially reducing foal mortality
- •Rhodococcosis continues to present significant clinical challenges with inadequate prevention strategies; stay updated on emerging diagnostic and treatment approaches
- •Environmental management and early diagnosis are critical components of disease control on breeding farms
- •Current treatment options have limitations; consult with specialists for individual case management and consider enrollment in research initiatives
- •R. equi strains from non-equine sources (pigs, humans) can still cause severe disease in foals through alternative virulence mechanisms (VapK), complicating prevention and control strategies
- •Understanding that multiple plasmid types and virulence factors drive R. equi pathogenesis may inform development of more comprehensive diagnostic and therapeutic approaches for foal pneumonia
- •Cross-species transmission potential of R. equi with functional virulence factors warrants attention to biosecurity and source management in facilities with mixed animal populations
- •R. equi remains a significant bacterial pathogen affecting young foals in Poland; surveillance and molecular characterization help track strain prevalence and identify outbreak patterns
- •Understanding plasmid variants and virulence factors (pVapA) may inform diagnostic approaches and future treatment strategies for rhodococcosis management
- •Tracheobronchial aspiration is a viable diagnostic sampling method for confirming R. equi infection in living pneumonic foals
- •Young foals are immunologically immature and have reduced responsiveness to traditional vaccines during the first 3 months of life; vaccination timing strategies should account for delayed Th2 immunity development
- •Foals show increased susceptibility to certain pathogens like Rhodococcus equi due to delayed T-cell response development; heightened biosecurity and management protocols are warranted in the first year of life
- •Understanding the maturation timeline of different immune components (antibody types and T-cell responses) can inform prevention strategies and help clinicians establish more appropriate protective protocols for young horses
- •Recognize 'rattles' as a serious and often terminal condition; early detection through awareness of respiratory signs is critical as manifestations are advanced at clinical presentation
- •Implement comprehensive farm management practices alongside any vaccination program—management control strategies are essential to reduce disease challenge on stud farms
- •Stay informed on emerging genomic knowledge of R. equi virulence factors as this may lead to improved vaccines and management protocols in the future
Key Research Findings
Azithromycin-doxycycline achieved 98.8% recovery rate (80/81 foals) compared to azithromycin-rifampin at 100% (81/81), with a difference of 1.2% (90% CI: -0.78% to 3.5%)
Both treatment combinations were significantly more effective than untreated controls (73% recovery, 57/78 foals)
Azithromycin-doxycycline was non-inferior to azithromycin-rifampin within the predetermined 10% non-inferiority margin
Results are specific to a single farm endemic for R. equi and may not generalize to other locations
High-dose R. equi inoculum (1×10⁸ CFU) produced significantly greater lung involvement (31.8% vs 14.4%) compared to low-dose (1×10⁷ CFU)
Polysynovitis developed in 20 of 28 foals (71%) and uveitis in 14 of 25 foals (56%), with significantly higher risk in high-inoculum group
R. equi was cultured from aqueous humor in 11 foals and synovial fluid in 14 foals, indicating direct septic infection rather than purely immune-mediated disease
Aqueous humor protein concentration was significantly elevated in high-inoculum group, correlating with disease severity
All three macrolides (erythromycin, azithromycin, clarithromycin) suppressed sweating in foals, with erythromycin being most potent
Clarithromycin and azithromycin induced less sweat suppression than erythromycin
Rifampicin alone had no effect on sweating but slightly reduced erythromycin-induced anhidrosis on Day 1 of treatment only
Macrolide-induced anhidrosis persisted through the 39-day observation period despite concurrent rifampicin administration
88% of placebo-treated foals (22/25) recovered without antimicrobial treatment
Disease progression rates did not differ significantly between any treatment groups (P > 0.05)
Azithromycin-rifampin shortened median treatment duration to 46 days versus 73 days for placebo, but ultrasonographic lesion resolution time was not significantly different between groups
Evidence Base
Efficacy of the combination of doxycycline and azithromycin for the treatment of foals with mild to moderate bronchopneumonia.
Wetzig Maria, Venner Monica, Giguère Steeve (2020) — Equine veterinary journal
Development of septic polysynovitis and uveitis in foals experimentally infected with Rhodococcus equi.
Huber Laura, Giguère Steeve, Berghaus Londa J et al. (2018) — PloS one
Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals.
Stieler Stewart A L, Sanchez L C, Mallicote M F et al. (2017) — Equine veterinary journal
Efficacy of mass antimicrobial treatment of foals with subclinical pulmonary abscesses associated with Rhodococcus equi.
Venner M, Astheimer K, Lämmer M et al. (2013) — Journal of veterinary internal medicine
Serum cortisol concentrations in newborn foals are increased by transfusion with anti-rhodococcal hyperimmune plasma and inversely associated with immunoglobulin activity.
Sayre Kira C, Flores-Ahlschwede Patricia, Wethington Alexandra B et al. (2026) — Journal of equine veterinary science
Plasma metabolome of healthy and Rhodococcus equi-infected foals over time.
Sanclemente Jorge L, Rivera-Velez Sol M, Horohov David W et al. (2023) — Equine veterinary journal
Retrospective analysis of post-mortem findings in Thoroughbreds aged from birth to 18 months presented to a UK pathology laboratory.
Mouncey R, Arango-Sabogal J C, de Mestre A M et al. (2022) — Veterinary journal (London, England : 1997)
Culturable Microbial Population From the Upper Respiratory Tract of 1,010 Clinically Healthy Horses in Southern Brazil.
Espíndola Julia Pires, Machado Gustavo, Diehl Gustavo Nogueira et al. (2022) — Journal of equine veterinary science
Plasma lipidome of healthy and Rhodococcus equi-infected foals over time.
Sanclemente Jorge L, Rivera-Velez Sol Maiam, Dasgupta Nairanjana et al. (2022) — Equine veterinary journal
Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals.
Berlin S, Wallstabe S, Scheuch E et al. (2018) — Equine veterinary journal
Air sampling in the breathing zone of neonatal foals for prediction of subclinical Rhodococcus equi infection.
Chicken C, Muscatello G, Freestone J et al. (2012) — Equine veterinary journal
Whole-genome sequencing and pathogenicity analysis of Rhodococcus equi isolated in horses.
Hu Bin, Gao Sichao, Zhang Hao et al. (2024) — BMC veterinary research
Sting Reinhard, Schwabe Ingo, Kieferle Melissa et al. (2022) — Animals : an open access journal from MDPI
Ion Channel and Ubiquitin Differential Expression during Erythromycin-Induced Anhidrosis in Foals.
Patterson Rosa Laura, Mallicote Martha F, MacKay Robert J et al. (2021) — Animals : an open access journal from MDPI
Salazar-Rodríguez Daniel, Aleaga-Santiesteban Yamilé, Iglesias Enrique et al. (2021) — Frontiers in veterinary science
Age-related changes following in vitro stimulation with Rhodococcus equi of peripheral blood leukocytes from neonatal foals.
Kachroo Priyanka, Ivanov Ivan, Seabury Ashley G et al. (2013) — PloS one
Transfer of the virulence-associated protein a-bearing plasmid between field strains of virulent and avirulent Rhodococcus equi.
Stoughton W, Poole T, Kuskie K et al. (2013) — Journal of veterinary internal medicine
Abortion in a thoroughbred mare associated with an infection with avirulent Rhodococcus equi.
Nakamura Y, Nishi H, Katayama Y et al. (2007) — The Veterinary record
Two cases of equine abortion caused by Rhodococcus equi.
Szeredi L, Molnár T, Glávits R et al. (2006) — Veterinary pathology
Zanilabdin Makpal, Ilgekbayeva Gulnaz, Otarbayev Bauyrzhan et al. (2025) — Frontiers in veterinary science
Show 7 more references
Pilot study characterizing a single pooled preparation of equine platelet lysate for nebulization in the horse.
Egli Patricia, Boone Lindsey, Huber Laura et al. (2024) — Frontiers in veterinary science
Narváez Sonsiray Álvarez, Fernández Ingrid, Patel Nikita V et al. (2022) — Animals : an open access journal from MDPI
Current Trends in Understanding and Managing Equine Rhodococcosis.
Rakowska Alicja, Cywinska Anna, Witkowski Lucjan (2020) — Animals : an open access journal from MDPI
Identification of a VapA virulence factor functional homolog in Rhodococcus equi isolates housing the pVAPB plasmid.
Willingham-Lane Jennifer M, Coulson Garry B, Hondalus Mary K (2018) — PloS one
Molecular characterization of Rhodococcus equi isolates from horses in Poland: pVapA characteristics and plasmid new variant, 85-kb type V.
Witkowski Lucjan, Rzewuska Magdalena, Takai Shinji et al. (2017) — BMC veterinary research
The development of equine immunity: Current knowledge on immunology in the young horse.
Perkins G A, Wagner B (2015) — Equine veterinary journal
Rhodococcus equi infection in foals: the science of 'rattles'.
Muscatello G, Leadon D P, Klayt M et al. (2007) — Equine veterinary journal